UnitedHealth Stock News

UnitedHealth Group is rated Buy, with the worst seemingly behind and a clear path to margin recovery and earnings growth from 2026 onward. UNH's 2025 headwinds - higher medical expense ratio, Medicare Advantage pressures, and regulatory scrutiny - are being addressed through repricing, plan exits, and portfolio optimization. Valuation remains compelling: UNH trades at multi-year low multiples, ...

An analyst raised his price target on the health insurer by 14%. He also kept his buy recommendation intact.

UnitedHealth has been facing multiple headwinds recently, including rising costs and increasing utilization rates. The company has been growing, and last quarter, it raised its guidance.

UnitedHealth (UNH +0.60%) stock is testing the patience of investors.

UnitedHealth Group is navigating soaring costs and a volatile political landscape. The company is raising its premiums to address its collapsing margins.

UnitedHealth Group Incorporated is positioned for a multi-year turnaround, with 2026 marking the inflection and 2027 expected to deliver significant margin expansion. UNH's exit from Latin America, including a $1 billion Banmedica sale, strengthens the balance sheet and supports dividends and future buybacks. Despite elevated medical cost ratios and recent earnings pressure, UNH's Q3 revenue gr...

Luigi Mangione has watched surveillance videos of the killing of UnitedHealthcare CEO Brian Thompson at a court appearance.

UnitedHealth Group has agreed to sell its last South American business Banmedica to Brazilian private equity group Patria Investments for $1 billion, two sources with knowledge of the matter said on Sunday.